ALTSTATION.IO

The Cooper Companies, Inc. (COO) Stock Analysis

By Nova Skye | AltStation.io | Updated February 07, 2026

Price

$81.62

Change

+1.90%

Market Cap

$16.23B

Avg Volume

2.6M

Company Overview

The Cooper Companies, Inc. develops and sells products primarily for contact lens wearers and women’s healthcare. Headquartered in San Ramon, California, the company operates through two segments: CooperVision and CooperSurgical. CooperVision provides a variety of contact lenses suited to different vision needs, such as astigmatism and presbyopia. CooperSurgical focuses on family and women’s health, offering fertility products, medical devices, contraceptives, and cryostorage services like cord blood storage. Their customers include healthcare professionals, hospitals, clinics, and retailers.

Cooper is a leader in the contact lens market, leveraging its strong brand presence and innovative products. The company’s edge comes from its broad portfolio that addresses diverse vision challenges and its growing Women’s Health segment. However, they face competition from major players like Johnson & Johnson and Alcon, which could threaten market share. Overall, Cooper is well-positioned, but keeping pace with innovation is crucial to fend off competition.

Currently, Cooper is in a growth phase, driven by increasing demand for contact lenses and expanding its portfolio in women’s health. Recent milestones include enhancements to their product lines and strategic acquisitions that strengthen their market presence. As of now, the company reports solid revenue growth, indicating a robust demand for both its segments and underscoring the effectiveness of their strategic initiatives.

Key Financials

Market Cap

$16.23B

Revenue

$4.09B

EBITDA

$1.06B

Gross Margin

65.5%

Profit Margin

9.2%

Revenue Growth

4.6%

Total Cash

$110.60M

Total Debt

$2.78B

Free Cash Flow

$376.59M

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

43.65

Forward P/E

16.47

Beta

1.03

52-Week High

$95.43

52-Week Low

$61.78

EPS

$1.87

50-Day Avg

$81.00

200-Day Avg

$74.75

Price/Book

1.94

Technical Analysis

The Cooper Companies, Inc. (COO) has exhibited a declining trend over the past 52 weeks, with a notable decrease of 12.3% from its peak in February near $95. The price action indicates significant resistance at this level, as the stock failed to sustain above it multiple times following a peak in early March. Key support levels can be identified around $70 and $75; the stock saw brief support at these levels during June and July before continuing its downward trajectory. In the recent weeks, the stock has shown consolidation around the current price of $81.62, hovering just below the short-term resistance at $82.1. This price is still within the lower range of its 52-week span, which suggests potential bearish sentiment in the near term. The combination of resistance and recent low momentum indicates the necessity for a confirmed breakout above $82 for a bullish reversal.

Recent News and Developments

Here are the latest news and developments for The Cooper Companies, Inc

(COO) stock in the past week:

Market Update

### William Blair Upgrades Cooper Companies to Strong-Buy

On January 31, 2026, William Blair upgraded The Cooper Companies (COO) to a “strong-buy” rating

This upgrade contributes to a “Moderate Buy” consensus rating from analysts, with an average price target of $90.85. Additionally, Needham & Company LLC maintained a “Buy” rating for Cooper Companies on February 3, 2026, with a price target of $99.00.

Market Sentiment and Analyst Recommendations

Bull Case

William Blair’s strong-buy upgrade and Needham’s $99 price target suggest institutional confidence in upside. The company is beating earnings estimates consistently — a +0.24% positive ESP signals another beat likely on March 5. Revenue growth of 4.6% in a mature medical device space is solid, and the contact lens and eye care market has structural tailwinds from aging populations and increasing myopia rates. The stock is trading at 43.65x P/E, which is elevated, but justified if earnings growth accelerates post-Q1. The credit agreement extension to 2031 removes refinancing risk and gives management breathing room to execute. At $81.62, the stock sits 10.2% below the $91 analyst target, offering a clean risk-reward if the company can break above $82 resistance and sustain momentum into earnings.

Bear Case

The 43.65x P/E is the real problem here — it’s priced for perfection in a company growing revenue at just 4.6%. The stock has already declined 12.3% from its February peak near $95, and it’s failed multiple times to sustain above resistance, which signals weak conviction among buyers. Total debt of $2.78B against only $110.60M in cash is a concerning 25:1 ratio, leaving little margin for error if revenue growth stalls or margins compress. The consolidation around $81.62 could easily break downward if Q1 earnings disappoint even slightly given the high expectations baked in. Medical device competition is relentless, and Cooper’s core contact lens business faces pricing pressure from both direct competitors and online retailers. The chart shows the stock has been range-bound and struggling for months — this isn’t a stock with momentum.

What to Watch

Mark March 5, 2026 on your calendar for Q1 earnings. The bar is high given the positive ESP and recent upgrades, so beats need to be substantial and guided higher to justify the valuation. Watch for gross margin trends — any compression would be a red flag in a business trading at 44x earnings. The $82 level is critical resistance; if Cooper breaks and holds above it on volume, the $91 target becomes realistic. Monitor debt reduction progress and free cash flow generation; management needs to prove it can delever while still investing in growth. Keep an eye on contact lens market share data and pricing trends in quarterly commentary. If guidance for 2026 revenue growth remains stuck below 5%, expect the valuation multiple to compress significantly regardless of earnings beats.

Analyst Consensus

BUY

Based on 16 analyst opinions

Low Target

$73.00

Mean Target

$91.00

High Target

$100.00

Earnings and Financial Data

Sector

Healthcare

Industry

Medical Instruments & Supplies

Employees

15,000

Earnings & Dividends

Next Earnings

Mar 05, 2026

EPS (Trailing)

$1.87

Dividend Yield

None

Payout Ratio

Frequently Asked Questions

Is COO a good stock to buy?

Yes, analysts recommend a “BUY” for The Cooper Companies, Inc. (COO), with a target price of $91.00. The stock currently trades at $81.62, offering potential upside of about 11.5%.

What is COO’s price target?

The analyst price target for COO is $91.00. This indicates a significant upside given the current trading price of $81.62, suggesting that the stock may be undervalued.

Does COO pay a dividend?

No, The Cooper Companies currently does not pay a dividend. This may deter income-focused investors, but the focus on growth could appeal to others.

What is COO’s P/E ratio?

COO has a trailing P/E ratio of 43.65 and a forward P/E of 16.47. The high trailing P/E suggests that the stock is quite expensive relative to its earnings, but the forward P/E indicates better value may come in the future.

What is COO’s market capitalization?

The Cooper Companies has a market capitalization of $16.23 billion. This positions the company as a mid-cap player in the medical instruments and supplies sector, providing a solid foundation for growth.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated February 07, 2026.